Claims for Patent: 6,872,397

Summary for Patent: 6,872,397

Title:	Method for treating neuromuscular disorders and conditions with botulinum toxin types A and B
Abstract:	A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.
Inventor(s):	Aoki; K. Roger (Laguna Hills, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Nigel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	09/812,113
Patent Claims:	1. A method of treating a patient suffering from a dystonial the method comprising intramuscular or subcutaneous administration to the patient of up to 1,000 units of a botulinum toxin type A per patient treatment session until the patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction of or to substantially alleviate a symptom of the dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B to thereby again achieve a marked reduction or a substantial alleviation of a symptom of the dystonia. 2. The method of claim 1, wherein the dystonia is cervical dystonia. 3. A method of treating cervical dystonia in a patient, the method comprising intramuscular or subcutaneous administration to a patient with dystonia of up to 1,000 units of a botulinum toxin type A per patient treatment session until th patient experiences loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to achieve a marked reduction of a symptom of the cervical dystonia, and thereafter administering to the patient at least about 80 units of a botulinum toxin type B. 4. The method of claim 3, wherein treating the cervical dystonia reduces the severity of an abnormal head position symptom of the cervical dystonia. 5. The method of claim 3, wherein treating the cervical dystonia reduces a neck pain associated with the cervical dystonia.

Details for Patent 6,872,397

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2013-06-10

International Patent Family for US Patent 6,872,397

Country	Patent Number	Estimated Expiration
Australia	689115
Australia	7087894
Australia	7319398
Canada	2164866